Wells Fargo
LBRX

Wells Fargo’s LB Pharmaceuticals LBRX Stock Holding History

Wells Fargo’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$213K Sell
8,623
-13,680
-61% -$316K ﹤0.01% 4673
2025
Q4 		$496K Buy
22,303
+21,303
+2,130% +$372K ﹤0.01% 4502
2025
Q3 		$15.8K Buy
+1,000
New +$15.9K ﹤0.01% 5850

Other funds holding LBRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Wells Fargo's LBRX Position: Q1 2026 in Review

Wells Fargo reduced its LB Pharmaceuticals (LBRX) stake by 61% in Q1 2026, selling an estimated $316K and leaving 8,623 shares worth $213K. The position accounts for ﹤0.01% of the portfolio, ranked #4673.

Wells Fargo first reported a position in LBRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $496K in Q4 2025. 77 funds tracked by Wall St. Rank hold LBRX as of Q1 2026.

  • Wells Fargo held 8,623 shares of LB Pharmaceuticals worth $213K as of Q1 2026.
  • Wells Fargo sold 13,680 LB Pharmaceuticals shares in Q1 2026, an estimated $316K.
  • LB Pharmaceuticals made up ﹤0.01% of Wells Fargo's portfolio in Q1 2026, its #4673 holding.
  • Wells Fargo first reported a position in LB Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Wells Fargo's LB Pharmaceuticals position peaked at $496K in Q4 2025.
  • 77 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q1 2026.

Based on Wells Fargo's 13F filing for Q1 2026, filed 11 May 2026.